MX2017000082A - Composiciones y metodos para mejorar terapias con celulas adoptivas. - Google Patents
Composiciones y metodos para mejorar terapias con celulas adoptivas.Info
- Publication number
- MX2017000082A MX2017000082A MX2017000082A MX2017000082A MX2017000082A MX 2017000082 A MX2017000082 A MX 2017000082A MX 2017000082 A MX2017000082 A MX 2017000082A MX 2017000082 A MX2017000082 A MX 2017000082A MX 2017000082 A MX2017000082 A MX 2017000082A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- stabilizers
- integrin
- adoptive cell
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000011467 adoptive cell therapy Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000003381 stabilizer Substances 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 2
- 102000006495 integrins Human genes 0.000 abstract 2
- 108010044426 integrins Proteins 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 201000005787 hematologic cancer Diseases 0.000 abstract 1
- 230000008595 infiltration Effects 0.000 abstract 1
- 238000001764 infiltration Methods 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1777—Integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se describen composiciones y métodos para mejorar la potencia y eficacia de una terapia con células adoptivas al utilizar estabilizadores con ligandos de integrina, en donde la integrina se selecciona del grupo que consiste de a4ß1, a5ß1, a4ß7, avß3 y aLß2, y poner en contacto las células efectoras ex vivo con agonistas o estabilizadores que tengan la Fórmula general (I); los métodos para tratar células que expresan integrinas con estos estabilizadores para mejorar la infiltración tumoral; y los métodos terapéuticos que comprenden administrar un estabilizador o células tratadas con agonistas a un mamífero que requiera del tratamiento de tumores sólidos, cánceres hematológicos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462019793P | 2014-07-01 | 2014-07-01 | |
| PCT/US2015/038447 WO2016003980A1 (en) | 2014-07-01 | 2015-06-30 | Compositions and methods to improve adoptive cell therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017000082A true MX2017000082A (es) | 2017-05-30 |
Family
ID=55016230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017000082A MX2017000082A (es) | 2014-07-01 | 2015-06-30 | Composiciones y metodos para mejorar terapias con celulas adoptivas. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11484524B2 (es) |
| EP (1) | EP3164127A4 (es) |
| JP (1) | JP2017521435A (es) |
| CN (1) | CN106604727A (es) |
| AU (2) | AU2015284263B2 (es) |
| CA (1) | CA2954175C (es) |
| MX (1) | MX2017000082A (es) |
| WO (1) | WO2016003980A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11484524B2 (en) | 2014-07-01 | 2022-11-01 | 7 Hills Pharma LLC | Compositions and methods to improve adoptive cell therapies |
| US11311619B2 (en) | 2016-04-28 | 2022-04-26 | 7 Hills Pharma Inc. and Texas Heart Institute | Integrin activator vaccine compositions |
| MX2017013859A (es) | 2015-04-29 | 2018-07-06 | 7 Hills Interests Llc | Composiciones novedosas y metodos para inmunoterapias que comprenden adyuvantes del agonistas del ligando receptor de integrina de molecula pequeña. |
| US20180184610A1 (en) * | 2018-01-31 | 2018-07-05 | Nunhems B.V. | Spinach variety nun 06303 sps |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3563799A (en) | 1998-04-16 | 1999-11-01 | Texas Biotechnology Corporation | Compounds that inhibit the binding of integrins to their receptors |
| US20020022032A1 (en) * | 1999-04-23 | 2002-02-21 | Curry Patrick Mark | Immuno-adjuvant PDT treatment of metastatic tumors |
| KR101000358B1 (ko) * | 2010-04-29 | 2010-12-13 | 서울대학교산학협력단 | 인테그린 αⅤβ３ 결합성 지질 유도체 및 그를 포함하는 지질 나노입자 |
| CA2997471C (en) * | 2010-11-16 | 2020-12-01 | Texas Heart Institute | Agonists that enhance binding of integrin-expressing cells to integrin receptors |
| ES2910654T3 (es) | 2014-02-12 | 2022-05-13 | 7 Hills Pharma LLC | Composiciones y métodos para mejorar la migración y el injerto de células madre hematopoyéticas |
| US11484524B2 (en) | 2014-07-01 | 2022-11-01 | 7 Hills Pharma LLC | Compositions and methods to improve adoptive cell therapies |
-
2015
- 2015-06-30 US US14/754,931 patent/US11484524B2/en active Active
- 2015-06-30 CA CA2954175A patent/CA2954175C/en active Active
- 2015-06-30 CN CN201580046658.9A patent/CN106604727A/zh active Pending
- 2015-06-30 EP EP15815125.8A patent/EP3164127A4/en not_active Ceased
- 2015-06-30 AU AU2015284263A patent/AU2015284263B2/en active Active
- 2015-06-30 WO PCT/US2015/038447 patent/WO2016003980A1/en active Application Filing
- 2015-06-30 JP JP2017501152A patent/JP2017521435A/ja active Pending
- 2015-06-30 MX MX2017000082A patent/MX2017000082A/es unknown
-
2020
- 2020-10-26 US US17/080,195 patent/US20210145796A1/en active Pending
-
2021
- 2021-04-14 AU AU2021202260A patent/AU2021202260B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021202260A1 (en) | 2021-05-06 |
| JP2017521435A (ja) | 2017-08-03 |
| US20160000755A1 (en) | 2016-01-07 |
| AU2015284263A1 (en) | 2017-02-02 |
| US11484524B2 (en) | 2022-11-01 |
| CA2954175A1 (en) | 2016-01-07 |
| WO2016003980A1 (en) | 2016-01-07 |
| EP3164127A1 (en) | 2017-05-10 |
| AU2021202260B2 (en) | 2022-11-10 |
| US20210145796A1 (en) | 2021-05-20 |
| EP3164127A4 (en) | 2017-11-22 |
| AU2015284263B2 (en) | 2021-02-25 |
| CN106604727A (zh) | 2017-04-26 |
| CA2954175C (en) | 2023-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| MX2019008208A (es) | Métodos para tratar el cáncer con anticuerpos anti-tim-3. | |
| MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| EA201201186A1 (ru) | ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ | |
| WO2016106403A3 (en) | Therapeutic compositions and methods for malignant tumors with rnai molecules targeted to hsp47 and p21 | |
| MX2016013027A (es) | Uso de dianhidrogalactitol y analogos o derivados del mismo para tratar cancer de celulas no pequeñas del pulmon y cancer de ovario. | |
| PH12016502354A1 (en) | Pharmaceutical composition | |
| MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
| WO2015009726A3 (en) | Medical uses of cd38 agonists | |
| PH12015502855A1 (en) | Peptides and petidomimetics in combination uses and treatments for cancer patient subpopulations | |
| PH12015501552A1 (en) | Androgen receptor modulator and uses thereof | |
| AR082340A1 (es) | Metodos y composiciones para la terapia del cancer de higado | |
| EA201791094A1 (ru) | Аналоги простых эфиров фосфолипидов в качестве носителей лекарственных средств, нацеленных на раковые клетки | |
| MX2014012381A (es) | Terapia de combinacion para tratar cancer. | |
| EA201991622A1 (ru) | Комплексная терапия для лечения рака | |
| TW201613589A (en) | Combination methods for treating cancers | |
| EA201591987A1 (ru) | Лечение злокачественной опухоли дигидропиразинопиразинами | |
| EA201591543A1 (ru) | Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| MX2017000082A (es) | Composiciones y metodos para mejorar terapias con celulas adoptivas. | |
| MX2018000052A (es) | Composiciones y métodos para la terapia combinada con virus del dengue y celulas dendríticas. | |
| MX2018006776A (es) | Usos de pirimido-piridazinonas para tratar el cancer. | |
| MX2018004112A (es) | Terapia de combinacion racional para el tratamiento de cancer. | |
| MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
| RU2013130449A (ru) | Способ комбинированного лечения рака прямой кишки |